127 related articles for article (PubMed ID: 2456288)
21. Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban.
Varin R; Mirshahi S; Mirshahi P; Klein C; Jamshedov J; Chidiac J; Perzborn E; Mirshahi M; Soria C; Soria J
Thromb Res; 2013 Mar; 131(3):e100-9. PubMed ID: 23313382
[TBL] [Abstract][Full Text] [Related]
22. Plasminogen, plasminogen activator, and platelets in the regulation of clot lysis. Reconstitution and patient studies.
Carroll RC; Radcliffe RD; Taylor FB; Gerrard JM
J Lab Clin Med; 1982 Dec; 100(6):986-96. PubMed ID: 6890569
[TBL] [Abstract][Full Text] [Related]
23. An experimental and theoretical study on the dissolution of mural fibrin clots by tissue-type plasminogen activator.
Wootton DM; Popel AS; Alevriadou BR
Biotechnol Bioeng; 2002 Feb; 77(4):405-19. PubMed ID: 11787013
[TBL] [Abstract][Full Text] [Related]
24. Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induced lysis.
Parise P; Morini M; Agnelli G; Ascani A; Nenci GG
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):721-7. PubMed ID: 8292721
[TBL] [Abstract][Full Text] [Related]
25. In vitro studies on the fibrinolytic, thrombolytic and fibrinogenolytic properties of a tissue plasminogen activator from guinea pig keratocytes.
Electricwala A; Ling RJ; Sutton PM; Griffiths B; Riley PA; Atkinson T
Thromb Haemost; 1985 Apr; 53(2):200-3. PubMed ID: 4040659
[TBL] [Abstract][Full Text] [Related]
26. Acceleration of plasma clot lysis by an antibody to alpha 2-antiplasmin.
Reed GL; Matsueda GR; Haber E
Trans Assoc Am Physicians; 1988; 101():250-6. PubMed ID: 2480017
[No Abstract] [Full Text] [Related]
27. Compaction of fibrin clots reveals the antifibrinolytic effect of factor XIII.
Rijken DC; Abdul S; Malfliet JJ; Leebeek FW; Uitte de Willige S
J Thromb Haemost; 2016 Jul; 14(7):1453-61. PubMed ID: 27148673
[TBL] [Abstract][Full Text] [Related]
28. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
Sakharov DV; Barrertt-Bergshoeff M; Hekkenberg RT; Rijken DC
Thromb Haemost; 1999 Apr; 81(4):605-12. PubMed ID: 10235448
[TBL] [Abstract][Full Text] [Related]
29. Thrombin activatable fibrinolysis inhibitor (TAFI) does not inhibit in vitro thrombolysis by pharmacological concentrations of t-PA.
Colucci M; D'Aprile AM; Italia A; Gresele P; Morser J; Semeraro N
Thromb Haemost; 2001 Apr; 85(4):661-6. PubMed ID: 11341502
[TBL] [Abstract][Full Text] [Related]
30. Resistance of porcine blood clots to lysis relates to poor activation of porcine plasminogen by tissue plasminogen activator.
Flight SM; Masci PP; Lavin MF; Gaffney PJ
Blood Coagul Fibrinolysis; 2006 Jul; 17(5):417-20. PubMed ID: 16788320
[TBL] [Abstract][Full Text] [Related]
31. Retinoic acid enhances fibrinolytic activity in-vivo by enhancing tissue type plasminogen activator (t-PA) activity and inhibits venous thrombosis.
van Giezen JJ; Boon GI; Jansen JW; Bouma BN
Thromb Haemost; 1993 Apr; 69(4):381-6. PubMed ID: 8497851
[TBL] [Abstract][Full Text] [Related]
32. Incorporation of fragment X into fibrin clots renders them more susceptible to lysis by plasmin.
Schaefer AV; Leslie BA; Rischke JA; Stafford AR; Fredenburgh JC; Weitz JI
Biochemistry; 2006 Apr; 45(13):4257-65. PubMed ID: 16566600
[TBL] [Abstract][Full Text] [Related]
33. The role of alpha 2-antiplasmin in the inhibition of clot lysis in newborns and adults.
Ries M; Klinge J; Rauch R; Keuper H; Harms D
Biol Neonate; 1996; 69(5):298-306. PubMed ID: 8790908
[TBL] [Abstract][Full Text] [Related]
34. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
Matsuo O; Rijken DC; Collen D
Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
[TBL] [Abstract][Full Text] [Related]
35. TAFIa, PAI-1 and alpha-antiplasmin: complementary roles in regulating lysis of thrombi and plasma clots.
Mutch NJ; Thomas L; Moore NR; Lisiak KM; Booth NA
J Thromb Haemost; 2007 Apr; 5(4):812-7. PubMed ID: 17388801
[TBL] [Abstract][Full Text] [Related]
36. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
Watahiki Y; Scully MF; Ellis V; Kakkar VV
Thromb Haemost; 1989 Jun; 61(3):502-6. PubMed ID: 2508259
[TBL] [Abstract][Full Text] [Related]
37. Significance of cross-linking of alpha 2-plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis.
Sakata Y; Aoki N
J Clin Invest; 1982 Mar; 69(3):536-42. PubMed ID: 7199538
[TBL] [Abstract][Full Text] [Related]
38. The effect of 40 kHz ultrasound on tissue plasminogen activator-induced clot lysis in three in vitro models.
Pieters M; Hekkenberg RT; Barrett-Bergshoeff M; Rijken DC
Ultrasound Med Biol; 2004 Nov; 30(11):1545-52. PubMed ID: 15588966
[TBL] [Abstract][Full Text] [Related]
39. Qualitative description of factors involved in the retraction and lysis of dilute whole blood clots and in the aggregation and retraction of platelets.
Taylor FB; Müller-Eberhard HJ
J Clin Invest; 1970 Nov; 49(11):2068-85. PubMed ID: 4248913
[TBL] [Abstract][Full Text] [Related]
40. Fibrin clot lysis by tissue plasminogen activator (tPA) is impaired in plasma from pediatric patients undergoing orthotopic liver transplantation.
Leaker MT; Brooker LA; Mitchell LG; Weitz JI; Superina R; Andrew ME
Transplantation; 1995 Jul; 60(2):144-7. PubMed ID: 7624956
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
